Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 naive T cells and D1-like receptor antagonist SCH-23390 inhibits cartilage destruction in a human rheumatoid arthritis/SCID mouse chimera model

Kazuhisa Nakano, Kunihiro Yamaoka, Kentaro Hanami, Kazuyoshi Saito, Yasuyuki Sasaguri, Nobuyuki Yanagihara, Shinya Tanaka, Ichiro Katsuki, Sho Matsushita, Yoshiya Tanaka

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

A major neurotransmitter dopamine transmits signals via five different seven-transmembrane G protein-coupled receptors termed D1-D5. Several studies have shown that dopamine not only mediates interactions into the nervous system, but can contribute to the modulation of immunity via receptors expressed on immune cells. We have previously shown an autocrine/paracrine release of dopamine by dendritic cells (DCs) during Ag presentation to naive CD4 + T cells and found efficacious results of a D1-like receptor antagonist SCH-23390 in the experimental autoimmune encephalomyelitis mouse model of multiple sclerosis and in the NOD mouse model of type I diabetes, with inhibition of Th17 response. This study aimed to assess the role of dopaminergic signaling in Th17-mediated immune responses and in the pathogenesis of rheumatoid arthritis (RA). In human naive CD4+ T cells, dopamine increased IL-6-dependent IL-17 production via D1-like receptors, in response to anti-CD3 plus anti-CD28 mAb. Furthermore, dopamine was localized with DCs in the synovial tissue of RA patients and significantly increased in RA synovial fluid. In the RA synovial/SCID mouse chimera model, although a selective D2-like receptor antagonist haloperidol significantly induced accumulation of IL-6 + and IL-17+ T cells with exacerbated cartilage destruction, SCH-23390 strongly suppressed these responses. Taken together, these findings indicate that dopamine released by DCs induces IL-6-Th17 axis and causes aggravation of synovial inflammation of RA, which is the first time, to our knowledge, that actual evidence has shown the pathological relevance of dopaminergic signaling with RA.

Original languageEnglish
Pages (from-to)3745-3752
Number of pages8
JournalJournal of Immunology
Volume186
Issue number6
DOIs
Publication statusPublished - 2011 Mar 15
Externally publishedYes

Fingerprint

CD4 Antigens
SCID Mice
Interleukin-17
Cartilage
Interleukin-6
Dopamine
Rheumatoid Arthritis
T-Lymphocytes
Dendritic Cells
Inbred NOD Mouse
Autoimmune Experimental Encephalomyelitis
Synovial Fluid
Haloperidol
Type 1 Diabetes Mellitus
Nervous System
Multiple Sclerosis
Neurotransmitter Agents
SCH 23390
Immunity
Inflammation

ASJC Scopus subject areas

  • Immunology

Cite this

Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 naive T cells and D1-like receptor antagonist SCH-23390 inhibits cartilage destruction in a human rheumatoid arthritis/SCID mouse chimera model. / Nakano, Kazuhisa; Yamaoka, Kunihiro; Hanami, Kentaro; Saito, Kazuyoshi; Sasaguri, Yasuyuki; Yanagihara, Nobuyuki; Tanaka, Shinya; Katsuki, Ichiro; Matsushita, Sho; Tanaka, Yoshiya.

In: Journal of Immunology, Vol. 186, No. 6, 15.03.2011, p. 3745-3752.

Research output: Contribution to journalArticle

Nakano, Kazuhisa ; Yamaoka, Kunihiro ; Hanami, Kentaro ; Saito, Kazuyoshi ; Sasaguri, Yasuyuki ; Yanagihara, Nobuyuki ; Tanaka, Shinya ; Katsuki, Ichiro ; Matsushita, Sho ; Tanaka, Yoshiya. / Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 naive T cells and D1-like receptor antagonist SCH-23390 inhibits cartilage destruction in a human rheumatoid arthritis/SCID mouse chimera model. In: Journal of Immunology. 2011 ; Vol. 186, No. 6. pp. 3745-3752.
@article{62db3ea17a234b15b9319a6e57f0af11,
title = "Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 naive T cells and D1-like receptor antagonist SCH-23390 inhibits cartilage destruction in a human rheumatoid arthritis/SCID mouse chimera model",
abstract = "A major neurotransmitter dopamine transmits signals via five different seven-transmembrane G protein-coupled receptors termed D1-D5. Several studies have shown that dopamine not only mediates interactions into the nervous system, but can contribute to the modulation of immunity via receptors expressed on immune cells. We have previously shown an autocrine/paracrine release of dopamine by dendritic cells (DCs) during Ag presentation to naive CD4 + T cells and found efficacious results of a D1-like receptor antagonist SCH-23390 in the experimental autoimmune encephalomyelitis mouse model of multiple sclerosis and in the NOD mouse model of type I diabetes, with inhibition of Th17 response. This study aimed to assess the role of dopaminergic signaling in Th17-mediated immune responses and in the pathogenesis of rheumatoid arthritis (RA). In human naive CD4+ T cells, dopamine increased IL-6-dependent IL-17 production via D1-like receptors, in response to anti-CD3 plus anti-CD28 mAb. Furthermore, dopamine was localized with DCs in the synovial tissue of RA patients and significantly increased in RA synovial fluid. In the RA synovial/SCID mouse chimera model, although a selective D2-like receptor antagonist haloperidol significantly induced accumulation of IL-6 + and IL-17+ T cells with exacerbated cartilage destruction, SCH-23390 strongly suppressed these responses. Taken together, these findings indicate that dopamine released by DCs induces IL-6-Th17 axis and causes aggravation of synovial inflammation of RA, which is the first time, to our knowledge, that actual evidence has shown the pathological relevance of dopaminergic signaling with RA.",
author = "Kazuhisa Nakano and Kunihiro Yamaoka and Kentaro Hanami and Kazuyoshi Saito and Yasuyuki Sasaguri and Nobuyuki Yanagihara and Shinya Tanaka and Ichiro Katsuki and Sho Matsushita and Yoshiya Tanaka",
year = "2011",
month = "3",
day = "15",
doi = "10.4049/jimmunol.1002475",
language = "English",
volume = "186",
pages = "3745--3752",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "6",

}

TY - JOUR

T1 - Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 naive T cells and D1-like receptor antagonist SCH-23390 inhibits cartilage destruction in a human rheumatoid arthritis/SCID mouse chimera model

AU - Nakano, Kazuhisa

AU - Yamaoka, Kunihiro

AU - Hanami, Kentaro

AU - Saito, Kazuyoshi

AU - Sasaguri, Yasuyuki

AU - Yanagihara, Nobuyuki

AU - Tanaka, Shinya

AU - Katsuki, Ichiro

AU - Matsushita, Sho

AU - Tanaka, Yoshiya

PY - 2011/3/15

Y1 - 2011/3/15

N2 - A major neurotransmitter dopamine transmits signals via five different seven-transmembrane G protein-coupled receptors termed D1-D5. Several studies have shown that dopamine not only mediates interactions into the nervous system, but can contribute to the modulation of immunity via receptors expressed on immune cells. We have previously shown an autocrine/paracrine release of dopamine by dendritic cells (DCs) during Ag presentation to naive CD4 + T cells and found efficacious results of a D1-like receptor antagonist SCH-23390 in the experimental autoimmune encephalomyelitis mouse model of multiple sclerosis and in the NOD mouse model of type I diabetes, with inhibition of Th17 response. This study aimed to assess the role of dopaminergic signaling in Th17-mediated immune responses and in the pathogenesis of rheumatoid arthritis (RA). In human naive CD4+ T cells, dopamine increased IL-6-dependent IL-17 production via D1-like receptors, in response to anti-CD3 plus anti-CD28 mAb. Furthermore, dopamine was localized with DCs in the synovial tissue of RA patients and significantly increased in RA synovial fluid. In the RA synovial/SCID mouse chimera model, although a selective D2-like receptor antagonist haloperidol significantly induced accumulation of IL-6 + and IL-17+ T cells with exacerbated cartilage destruction, SCH-23390 strongly suppressed these responses. Taken together, these findings indicate that dopamine released by DCs induces IL-6-Th17 axis and causes aggravation of synovial inflammation of RA, which is the first time, to our knowledge, that actual evidence has shown the pathological relevance of dopaminergic signaling with RA.

AB - A major neurotransmitter dopamine transmits signals via five different seven-transmembrane G protein-coupled receptors termed D1-D5. Several studies have shown that dopamine not only mediates interactions into the nervous system, but can contribute to the modulation of immunity via receptors expressed on immune cells. We have previously shown an autocrine/paracrine release of dopamine by dendritic cells (DCs) during Ag presentation to naive CD4 + T cells and found efficacious results of a D1-like receptor antagonist SCH-23390 in the experimental autoimmune encephalomyelitis mouse model of multiple sclerosis and in the NOD mouse model of type I diabetes, with inhibition of Th17 response. This study aimed to assess the role of dopaminergic signaling in Th17-mediated immune responses and in the pathogenesis of rheumatoid arthritis (RA). In human naive CD4+ T cells, dopamine increased IL-6-dependent IL-17 production via D1-like receptors, in response to anti-CD3 plus anti-CD28 mAb. Furthermore, dopamine was localized with DCs in the synovial tissue of RA patients and significantly increased in RA synovial fluid. In the RA synovial/SCID mouse chimera model, although a selective D2-like receptor antagonist haloperidol significantly induced accumulation of IL-6 + and IL-17+ T cells with exacerbated cartilage destruction, SCH-23390 strongly suppressed these responses. Taken together, these findings indicate that dopamine released by DCs induces IL-6-Th17 axis and causes aggravation of synovial inflammation of RA, which is the first time, to our knowledge, that actual evidence has shown the pathological relevance of dopaminergic signaling with RA.

UR - http://www.scopus.com/inward/record.url?scp=79953185365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953185365&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1002475

DO - 10.4049/jimmunol.1002475

M3 - Article

C2 - 21307293

AN - SCOPUS:79953185365

VL - 186

SP - 3745

EP - 3752

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 6

ER -